"Moderna's Next-Gen COVID Vaccine Surpasses Approved Version in Phase 3 Trials"
TL;DR Summary
Moderna is moving three experimental vaccines for norovirus, Epstein-Barr virus, and varicella-zoster virus into final stage studies as it seeks to diversify its product portfolio beyond the Covid-19 vaccine. The company also announced positive clinical trial data on its "next-generation" Covid-19 shot and entered a funding agreement with Blackstone Life Sciences to advance its flu shot program. Moderna's CEO emphasized the focus on execution to address significant unmet medical needs, but the company expects revenue to fall before growing again in 2025 and breaking even in 2026.
- Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump CNBC
- Moderna says new COVID shot hit goal in late-stage trial The Boston Globe
- Moderna’s new and improved COVID vaccine produced positive trial results MarketWatch
- Moderna’s New Covid-19 Vaccine Shows Positive Results Barron's
- Moderna's next-gen COVID vax surpasses approved version in phase 3 Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
18
Time Saved
4 min
vs 5 min read
Condensed
90%
871 → 87 words
Want the full story? Read the original article
Read on CNBC